TMPA

• UNSPSC Description:

  TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation[1][2].

• Target Antigen:

  AMPK; Nuclear Hormone Receptor 4A/NR4A

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PI3K/Akt/mTOR;Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/TMPA.html

• Purity:

  98.22

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  COC1=C(CC(OCC)=O)C(C(CCCCCCC)=O)=CC(OC)=C1OC

• Molecular Weight:

  380.48

• References & Citations:

  [1]Zhan YY, et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol. 2012 Nov;8(11):897-904. |[2]Recher, et al. Modulation of T-cell apoptosis by small molecule compounds targeting the nuclear orphan receptor Nur 77. (2018).

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1258275-73-8